- Home
- GDL vs ANIX Comparison
GDL vs ANIX Comparison
Compare GDL & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ANIX
- Stock Information
- Founded
- GDL 2006
- ANIX 1982
- Country
- GDL United States
- ANIX United States
- Employees
- GDL N/A
- ANIX N/A
- Industry
- GDL Investment Managers
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- ANIX Health Care
- Exchange
- GDL Nasdaq
- ANIX Nasdaq
- Market Cap
- GDL 95.6M
- ANIX 95.7M
- IPO Year
- GDL N/A
- ANIX 1987
- Fundamental
- Price
- GDL $8.47
- ANIX $4.27
- Analyst Decision
- GDL
- ANIX Strong Buy
- Analyst Count
- GDL 0
- ANIX 3
- Target Price
- GDL N/A
- ANIX $9.00
- AVG Volume (30 Days)
- GDL 11.2K
- ANIX 282.6K
- Earning Date
- GDL 01-01-0001
- ANIX 09-10-2025
- Dividend Yield
- GDL 6.02%
- ANIX N/A
- EPS Growth
- GDL N/A
- ANIX N/A
- EPS
- GDL N/A
- ANIX N/A
- Revenue
- GDL N/A
- ANIX N/A
- Revenue This Year
- GDL N/A
- ANIX N/A
- Revenue Next Year
- GDL N/A
- ANIX N/A
- P/E Ratio
- GDL N/A
- ANIX N/A
- Revenue Growth
- GDL N/A
- ANIX N/A
- 52 Week Low
- GDL $7.65
- ANIX $2.07
- 52 Week High
- GDL $8.13
- ANIX $4.98
- Technical
- Relative Strength Index (RSI)
- GDL 46.31
- ANIX 59.04
- Support Level
- GDL $8.44
- ANIX $4.21
- Resistance Level
- GDL $8.60
- ANIX $4.67
- Average True Range (ATR)
- GDL 0.07
- ANIX 0.36
- MACD
- GDL -0.01
- ANIX 0.02
- Stochastic Oscillator
- GDL 23.48
- ANIX 58.85
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.